10-Q: SWK Holdings Reports Strong Q3, Announces Merger with Runway Growth
Quarterly Report
SWK Holdings Corporation reported a significant increase in net income for Q3 2025 and announced a definitive merger agreement with Runway Growth Finance Corp., signaling a strategic pivot to its core finance business.
Summary
- Net income for the three months ended September 30, 2025, increased to $8.8 million, up from $3.5 million in the prior year period.
- Basic net income per share rose to $0.72 for Q3 2025, compared to $0.28 in Q3 2024.
- For the nine months ended September 30, 2025, net income was $16.9 million, a substantial increase from $7.6 million in the prior year period.
- The company entered into a definitive Agreement and Plan of Merger with Runway Growth Finance Corp. on October 9, 2025.
- SWK Holdings completed the sale of substantially all assets of its Pharmaceutical Development segment (MOD3) to Aptar for approximately $6.9 million on July 15, 2025, streamlining operations to focus on its Finance Receivables segment.
- Cash and cash equivalents increased to $10.2 million as of September 30, 2025, from $5.9 million at December 31, 2024.
- A special cash dividend of $4.00 per share, totaling $49.1 million, was paid on May 8, 2025.
Sentiment
Score: 8
Explanation: The company reported strong financial performance with significant increases in net income and EPS. The announcement of a definitive merger agreement with Runway Growth Finance Corp. and the successful divestiture of the Pharmaceutical Development segment represent major strategic positives, indicating a clear and focused future direction. While there was a decrease in total assets and equity, this was largely due to strategic asset sales and a substantial special dividend, which are generally viewed favorably by investors.
Positives
- Significant increase in net income for both the three and nine months ended September 30, 2025, driven by a benefit for credit losses and gains on warrants and asset sales.
- Strategic merger agreement with Runway Growth Finance Corp. provides a clear future direction and potential for shareholder value.
- Successful divestiture of the Pharmaceutical Development segment (MOD3) for approximately $6.9 million, allowing for a focused strategy on specialty finance.
- Strong cash flow generation from operating activities ($17.0 million for nine months) and investing activities ($45.8 million for nine months).
- Reduction in outstanding balance on the revolving credit facility to $0 as of September 30, 2025, from $6.2 million at December 31, 2024.
- A benefit for credit losses of $0.9 million for Q3 2025 and $1.6 million for the nine months, primarily due to the release of CECL reserves related to an early loan payoff.
Negatives
- Finance receivables, net, decreased by $32.4 million from $277.8 million at December 31, 2024, to $245.4 million at September 30, 2025.
- Total assets decreased by $42.8 million from $332.2 million at December 31, 2024, to $289.4 million at September 30, 2025.
- Total stockholders' equity decreased by $34.5 million from $288.7 million at December 31, 2024, to $254.2 million at September 30, 2025, partly due to the special cash dividend.
- A loss of $3.7 million was recognized on the revaluation of finance receivables for the nine months ended September 30, 2025, compared to a gain of $2.5 million in the prior year.
- Three finance receivables (Flowonix Medical, Inc., Best ABT, Inc., and Ideal Implant, Inc.) with a combined carrying value of $11.5 million are in non-accrual status.
- General and administrative expenses increased for both the three and nine months ended September 30, 2025, primarily due to increased legal fees and compensation costs.
Risks
- Exposure to a higher degree of credit risk associated with the life sciences sector due to concentration of finance receivables.
- Uncertainty in determining the allowance for credit losses, which could change materially in future periods due to economic conditions or borrower financial health.
- Subject to financial market risks, including changes in interest rates, which could affect net investment income, especially with floating rate debt.
- Potential adverse effects on business, financial condition, and results of operations from adverse developments in interest rates or hedging transactions (though no hedging is currently engaged in).
- Inflation could adversely affect partner companies' ability to pay interest and principal on loans if they cannot pass on cost increases to their customers.
- Litigation risks from the normal course of business, with uncertain outcomes that could have a material negative impact due to defense costs and diversion of management resources.
- The merger agreement is subject to terms and conditions, implying a risk of non-completion.
Future Outlook
The company's ability to generate future cash depends primarily on the success of its Finance Receivables business model, which involves providing capital to a broad range of life science companies, institutions, and inventors. It expects existing assets to generate positive cash flows during the remainder of 2025 and believes it is well-positioned to benefit from rising market interest rates due to its floating interest rate debt instruments.
Management Comments
- We believe we are well positioned to benefit should market interest rates rise in the future.
Industry Context
The merger with Runway Growth Finance Corp. signifies a strategic move towards consolidation and specialization within the life sciences specialty finance sector. The divestiture of the Pharmaceutical Development segment (MOD3) indicates a clear focus on the core finance receivables business, aligning with a trend of companies streamlining operations to enhance efficiency and leverage core competencies. This strategic shift positions SWK Holdings to potentially strengthen its market position in life sciences financing, especially given its emphasis on floating interest rate debt instruments in a rising interest rate environment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Merger Agreement | Company entered into an Agreement and Plan of Merger with Runway Growth Finance Corp., RWAY Portfolio Holding Corp., RWAY Portfolio Corp., and Runway Growth Capital LLC, outlining a multi-step merger process. | 2025-10-09 | This agreement will result in SWK Holdings Corporation becoming a wholly-owned subsidiary of Intermediary Sub, and ultimately merging into Runway Growth Finance Corp., fundamentally altering the corporate structure and ownership. |
| Key Stockholder Agreement | Double Black Diamond Offshore Ltd., holding approximately 69.9% of voting power, entered into an agreement to vote its shares in favor of the merger. | 2025-10-09 | Ensures significant shareholder support for the merger, increasing the likelihood of its successful completion. |
Legal Proceedings
- The company is involved in, or has been involved in, arbitrations or various other legal proceedings that arise from the normal course of its business.
- As of September 30, 2025, the company is not involved in any arbitration and/or other legal proceeding that it expects to have a material effect on its business, financial condition, results of operations and cash flows.
Related Party Transactions
- Key Stockholder Agreement with Double Black Diamond Offshore Ltd. and Black Diamond Offshore Ltd. to vote shares in favor of the merger. Double Black Diamond Offshore Ltd. held approximately 69.9% of the voting power of the Company Common Stock as of October 9, 2025.
Stakeholder Impact
- Shareholders will be directly impacted by the merger agreement with Runway Growth Finance Corp., which will involve a change in ownership structure. The special cash dividend of $4.00 per share provided a significant return.
- Employees of the Pharmaceutical Development segment (MOD3) were impacted by the asset sale to Aptar. The company now has 9 full-time employees, down from an unspecified number prior to the sale.
- Customers/Partners: The Finance Receivables segment continues to provide capital to life science companies, institutions, and inventors. The former customers of MOD3's CDMO services are now served by Aptar.
- Creditors: The company's debt obligations, including the 9.00% Senior Notes due 2027 and the revolving credit facility, will be affected by the merger, as the surviving entity will assume these liabilities or new arrangements will be made.
Next Steps
- Completion of the multi-step merger with Runway Growth Finance Corp.
- Continued focus on the Finance Receivables business model.
Key Dates
| Date | Description |
|---|---|
| 2023-06-28 | Company entered into a new revolving credit facility agreement with First Horizon Bank. |
| 2023-10-03 | Company issued $30.0 million aggregate principal amount of 9.00% Senior Notes due 2027. |
| 2023-10-10 | First Amendment to Credit Agreement, adding Woodforest National Bank as a lender and increasing aggregate commitments to $60.0 million. |
| 2023-10-27 | Underwriter exercised over-allotment option for an additional $3.0 million of 2027 Senior Notes. |
| 2024-01-01 | Effective date of Option and Asset Purchase Agreement with Aptar for MOD3 assets. |
| 2024-03-14 | Company entered into Option and Asset Purchase Agreement with Aptar. |
| 2024-04-01 | First option fee payment received from Aptar. |
| 2024-06-30 | Company exercised right to purchase AOTI, Inc. common shares. |
| 2024-08-29 | Amendment to Credit Agreement, adjusting consolidated interest coverage ratio, net charge-off percentage, and share repurchase limits. |
| 2025-02-01 | Second option fee payment received from Aptar. |
| 2025-04-10 | Company completed the sale of the majority of its finance receivables segment royalty portfolio to Soleus Capital for approximately $34.0 million in cash. |
| 2025-04-10 | Board of Directors declared a special cash dividend of $4.00 per share. |
| 2025-04-24 | Record date for the special cash dividend. |
| 2025-05-08 | Payment date for the special cash dividend. |
| 2025-05-19 | Board authorized a share repurchase program for up to $10.0 million until May 19, 2026. |
| 2025-05-29 | Company received 50,000 shares of Elutia, Inc. common stock as part of an amendment to an existing term loan finance receivable agreement. |
| 2025-07-15 | Company, MOD3, and Aptar closed the asset purchase agreement for the sale and assignment of MOD3 assets to Aptar. |
| 2025-08-11 | Current Share Repurchase Program was cancelled. |
| 2025-09-30 | End of the reporting period for the 10-Q filing. |
| 2025-10-09 | Company entered into an Agreement and Plan of Merger with Runway Growth Finance Corp. and its subsidiaries. |
| 2025-10-09 | Key Stockholder Agreement signed with Double Black Diamond Offshore Ltd. to vote in favor of the merger. |
| 2025-10-31 | Number of outstanding common shares was 12,095,906. |
| 2025-11-06 | Filing date of the Quarterly Report on Form 10-Q. |
Recommendation
strong buyThe filing presents a compelling case for a 'strong buy' recommendation. The announced merger with Runway Growth Finance Corp. is a transformative strategic move that provides a clear path for future growth and shareholder value, especially with the backing of a key stockholder holding 69.9% of voting power. Financially, the company delivered exceptionally strong Q3 2025 results, with net income more than doubling year-over-year, driven by a significant benefit for credit losses and gains from strategic asset sales and warrants. The divestiture of the Pharmaceutical Development segment streamlines operations, allowing for a focused approach on the higher-margin specialty finance business. The substantial special cash dividend paid earlier in the year also demonstrates a commitment to returning capital to shareholders. While total assets and equity decreased, this was largely a result of these strategic actions rather than operational underperformance. The company's strong cash position and ability to generate cash from its finance receivables portfolio further support a positive outlook.
Keywords
SWK Holdings, Runway Growth Finance Corp., Merger, Specialty Finance, Life Sciences, SEC 10-Q, Financial Results, Q3 2025, MOD3 Sale, Pharmaceutical Development, Finance Receivables, Senior Notes, Dividends, Warrants, Credit Losses, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.